SUMMARY Contrast sensitivity was measured by means of Arden grating plates in 100 patients on medication for pulmonary tuberculosis. The scores were abnormal in 38-2% of the patients whose therapy included ethambutol for three months, and 36*7% of the patients on similar treatment for six months. In comparison with age matched groups of patients on a regimen where streptomycin replaced ethambutol a statistically significant number of the patients on ethambutol had abnormal scores. This study suggests that Arden contrast sensitivity plates would be effective in detecting subclinical toxic optic neuropathy due to ethambutol and therefore could be used for routine monitoring of ocular function of patients on ethambutol. Loss of contrast sensitivity may explain why some patients on ethambutol with normal visual acuity and colour perception may still complain of visual disturbance.
Ethambutol hydrochloride is an orally administered agent specifically effective against Mycobacterium tuberculosis. Carr and Henkind' initially reported optic nerve toxicity due to ethambutol in 1962, and further reports have established this side effect as a dose related retrobulbar optic neuropathy. 2 In most studies it appears that the degree of reversibility depends on early recognition of symptoms and signs of ocular toxicity. 3 Since the introduction by Arden4 of a series of contrast gratings of various spatial frequencies, contrast sensitivity has been used to assess visual function in a number of ocular diseases. In When the sex of the patients whose medication included ethambutol is considered, the mean age of the females was 41*5 years and the males 44*4 years (statistically comparable ages). Of the patients on ethambutol who scored more than 82, 44% were females and 33% were males. This difference, however, is not statistically significant ( Table 2) .
The histogram in Fig. 1 is an analysis of the 100 patients divided by age in decades. Statistically there is no difference between the mean age of the four groups of patients between the ages of 20 and 49. In group A 34.6% scored more than 82, and in group B 28*6% were abnormal. In group C 9 5% were abnormal, and in group D 7.7% were abnormal. On statistical analysis a significant number of patients on ethambutol scored more than 82, compared with those not on ethambutol (p<0015 by Fisher's exact test). The mean scores were also significantly higher for patients on ethambutol (p<0-005 by paired t test) ( Table 3) .
When the patients between the ages of 20 and 49 who scored less than 83 were assessed, the mean scores of patients on ethambutol were similar to the mean scores of patients not on ethambutol. The 28 patients in groups A and B (mean age 33-1 years) had a mean score of 62-2 compared with the 31 patients in groups C and D (mean age 31-6 years) with a mean score of 59-8. There is no statistically significant difference between the mean scores of patients who scored less than 83, irrespective of whether they received ethambutol or not (Table 4) .
In a comparison of the patients who were on ethambutol who scored more than 82, the mean score of abnormal patients in group 1 who had received ethambutol for three months was 105-6 (standard deviation 19 1), while for abnormal patients in group 2 who had received ethambutol for six months the mean score was 110-4 (standard deviation . There is no statistically significant difference between the scores of these two groups.
When the age matched groups are considered, no single spatial frequency was particularly effective in detecting the effect of ethambutol on the optic nerve. The exact mechanism by which ethambutol produces retrobulbar neuritis is unknown. Experimentally in animals it has been shown that the drug can cause depletion of copper and zinc, with a decrease in cytochrome C oxidase activity.9 A relationship between these changes and ocular toxicity has not been established. It has also been suggested that, being a butanol derivative, ethambutol may cause toxic amblyopia by the same mechanism as alcohol."0 number of the patients whose medication included ethambutol had abnormal scores. Of the patients in the 3rd, 4th, and 5th decades of life, 34*6% were abnormal after three months and 28 6% abnormal after six months of ethambutol. 9-5% of the patients in the 3rd, 4th, and 5th decades who were not on ethambutol were abnormal after three months and 7-7% abnormal after six months. The three patients not on ethambutol who had abnormal contrast sensitivity scores were on a schedule that included streptomycin, isoniazide, rifampicin, and pyrazinamide. Two of these patients had normal eyes, and one was a corrected high myope who did not appear to have macular pathology on funduscopy. None had received previous tuberculosis treatment. The explanation for this finding may be that both isoniazide and streptomycin are optic nerve toxins, and, -although use of either of these agents with ethambutol may lower the toxic threshhold, they may be toxic on their own. '7 18 It has previously been reported that the toxic optic neuropathy secondary to ethambutol appears only after a latent period of 77 to 313 days following the beginning of treatment.12 It might therefore have been expected that more patients would be abnormal at six months than at three months. A possible reason why an almost similar number of patients had abnormal contrast sensitivity at three and six months (with similar mean scores) could be the fact that all the patients gained weight while in hospital. The ethambutol dose was kept constant for the entire sixmonth period, so the mg/kg dose gradually fell over this period to a mean dose of 22 mg/kg per day at six months.
The potential severity of ocular toxicity attributed to ethambutol, and the reversibility of the reaction when the drug is stopped, necessitate a screening procedure capable of detecting ocular toxic effects before a deficit occurs. It would appear that, for routine monitoring of ocular function of patients on ethambutol, Arden contrast sensitivity plates would be simple and effective. However, further study is required using serial testing in individual patients, in an attempt to disclose the onset of ethambutol toxic optic neuropathy and to establish the precise place of the test in the management of these patients. Loss of contrast sensitivity may explain why some patients on tuberculosis treatment who have normal visual acuity and colour perception may still complain of visual disturbance.
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